Is taurine a biomarker in autistic spectrum disorder?

Advances in Experimental Medicine and Biology

Volumn 975, Issue , 2017, Pages 3-16

  Park, Eunkyue ^a   Cohen, Ira ^a   Gonzalez, Maripaz ^a   Castellano, Mario R ^b   Flory, Michael ^a   Jenkins, Edmund C ^a   Brown, W Ted ^a   Schuller Levis, Georgia ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Antioxidant; ASD; Mitochondrial dysfunction; Taurine

Indexed keywords

BIOLOGICAL MARKER; PHENYL ISOTHIOCYANATE; TAURINE;

ADOLESCENT; ADULT; ARTICLE; AUTISM; BLOOD SAMPLING; CHEMICAL LABELING; CHILD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MARKER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PARENT; PATHOGENESIS; PRIORITY JOURNAL; SEX DIFFERENCE; SIBLING; BLOOD; PRESCHOOL CHILD;

ADOLESCENT; AUTISM SPECTRUM DISORDER; BIOMARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; TAURINE;

EID: 85029282882     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-94-024-1079-2_1     Document Type: Article

References (60)

1. Aldred S, Moore KM, Fitzgerald M, Waring RH (2003) Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 33(1):93–97
2. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DM5, 5th edn. Washington, DC
3. Arnold GL, Hyman SL, Mooney RA, Kirby RS (2003) Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies. J Autism Dev Disord 33(4):449–454
4. Ashwood P, Willis S, Van De Water J (2006) The immune response in autism: a new frontier for autism research. J Leukoc Biol 80:1–15
5. Bolte S, Poustka F (2002) The relation between general cognitive level and adaptive behavior domains in individuals with autism with and without co-morbid mental retardation. Child Psychiatry Hum Dev 33(2):165–172
6. Bourgeron T (2016) Current knowledge on the genetics of autism and propositions for future research. C R Biol 339(7–8):300–307. doi:10.1016/j.crvi.2016.05.004
7. CDC (2014) Community report on autism, https:\\www.cdc.gov/ncbddd/autism/states/comm_ report_autism_2014.pdf
8. Chauhan A, Chauhan V (2006) Oxidative stress in autism. Pathophysiology 13:171–181
9. Chawarska K, Shic F, Macari S, Campbell DJ, Brian J, Landa R, Hutman T, Nelson CA, Oznoff S, Tager-Flusberg H, Young GS (2014) 18-month predictors of later outcomes in younger siblings of children with autism spectrum disorder: a baby siblings research consortium study. J Am Acad Child Adolesc Psychiatry 53(12):1317–1327
10. Cohen IL (2003) Criterion-related validity of the PDD Behavior Inventory. J Autism Dev Disord 33(1):47–53
11. Cohen IL, Schmidt-Lackner S, Romanczyk R, Sudhalter V (2003) The PDD Behavior Inventory: a rating scale for assessing response to intervention in children with pervasive developmental disorder. J Autism Dev Disord 33(1):31–45
12. Cohen IL, Liu X, Hudson M, Gillis J, Cavalari RNS, Romanczyk RG, Karmel BZ, Gardner JM (2016) Using the PDD Behavior Inventory as a level 2 screener: a classification and regression trees analysis. J Autism Dev Disord 46:3006–3022
13. Erickson CA, Early M, Stigler KA, Wink LK, Mullett JE, McDougle CJ (2011) An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol 21(6):565–569
14. Frye RE, Rossignol DA (2011) Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res 69(5):41R–47R
15. Gaugler T, Klei L, Sanders S, Bodea C, Goldberg AP, Lee AB, Mahajan M, Manaa D, Pawitan Y, Reicher J, Ripke S, Sandin S, Sklar P, Svantesson O, Reichenberg A, Hultman CM, Devlin B, Roeder K, Buxbaum JD (2014) Most genetic risk for autism resides with common variation. Nat Genet 46:881–885
16. Geier DA, Kern JK, Garver CR, Adams JB, Audhya T, Geier MR (2009) A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem Res 34:386–393
17. Geschwind DH, State MW (2015) Gene hunting in autism spectrum disorder: on the path to precision medicine. Lancet Neurol 14(11):1109–1120
18. Ghabizadeh A (2013) Increased glutamate and homocysteine and decreased glutamine levels in autism: a review and strategies for future studies of amino acids in autism. Dis Markers 35(5):281–186
19. Giulivi C, Zhang YF, Omanska-Klusek A, Ross-Inta C, Wong S, Herts-picciotto I, Tassone F, Pessah IN (2011) Mitochondrial dysfunction in autism. JAMA 304(21):2389–2396
20. Hampson DR, Blatt GJ (2015) Autism spectrum disorders and neuropathology of the cerebellum. Front Neurosci 9:1–16
21. Huxtable R (1999) Expanding the circle 1975–1999: Sulfur biochemistry and insight on the biological functions of taurine. Adv Exp Med Biol 483:1–25
22. Jong CJ, Azuma J, Schaffer SW (2012) Mechanism underlying the antioxidant activity of taurine: prevention of mitochondrial oxidant production. Amino Acids 42:2223–2232
23. Junyent F, Utrera J, Romero R, Pallas M, Camins A, Duque D, Auladell C (2009) Prevention of epilepsy by taurine treatment in mice experimental model. J Neurosci Res 87:1500–1508
24. Kern JK, Geier DA, Adams JB, Garver CR, Audhya T, Geier MR (2011) A clinical trial of glutathione supplementation in autism spectrum disorders. Med Sci Monit 17(12):CR677–CR682
25. Lord C, Rutter M, Le Couteur A (1994) Autism diagnostic interview-a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659–685
26. Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, Pickeles A, Rutter M (2000) The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 30:205–223
27. 13C NMR-based urine metabolic profiling in autism spectrum disorders. Talanta 114:95–102
28. Ming X, Stein TP, Barnes V, Rhodes N, Guo L (2012) Metabolic perturbance in autism spectrum disorders: a metabolomics study. J Preteome Res 11(12):5856–5862
29. Moreno H, Borjas L, Arrieta A, Saez L, Prassad A, Estevez J, Bonilla E (1992) Clinical heterogeneity of the autistic syndrome: a study of 60 families. Investig Clin 33(1):13–31
30. Moreno-Fuenmayer H, Borjas L, Arrieta A, Valera V, Socorro-Candanoza L (1996) Plasma excitatory amino acids in autism. Investig Clin 37(2):113–128
31. Nakagawa Y, Chiba K (2016) Involvement of neuroinflammation during brain development in social cognitive deficits in autism spectrum disorder and schizophrenia. J Pharmacol Exp Ther 358(3):504–515
32. Naviaux JC, Schuchbauer MA, Li K, Wang L, Robrough VB, Powell SB, Naviaux RK (201Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipuinergtherapy. Transl Psychiatry 4:e400
33. Oliveira G, Diogo L, Ganzina M, Garcia P, Ataide A, Marques C, Miguel T, Borges L, OmcemAM, Oliveira CR (2005) Mitochondrial dysfunction in autism spectrum disorders: a populatiobased study. Dev Med Child Neurol 47:185–189
34. Onore C, Careaga M, Ashwood P (2012) The role of immune dysfunction in the pathophysioloof autism. Brain Behav Immun 26:383–392
35. Ozonoff S, Young GS, Carter A et al (2011) Recurrence risk for autism spectrum disorders: a siblings research consortium study. Pediatrics 128:e488–e495
36. Park E, Quinn MR, Wright CE, Schuller-Levis GB (1993) Taurine chloramine inhibits the synthsis of nitric oxide and the release of tumor factor in activated RAW 264.7 cells. J Leukoc 54:119–124
37. Park E, Schuller-Levis GB, Quinn MR (1995) Taurine chloramine inhibits production of oxide and TNF-α in activated RAW 264.7 cells by mechanisms that induce transcriptional translational events. J Immunol 154:4778–4784
38. Park E, Alberti J, Quinn MR, Schuller-Levis GB (1998) Taurine chloramine inhibits the productiof superoxide anion, IL-6 and IL-8 in activated human polymorphonuclear leukocytes. Schaffer S, Lombardini JB, Huxtable RJ (eds) Taurine 3 cellular and regulatory mechanism Plenum Press, New York, pp 177–182
39. Park E, Jia J, Quinn MR, Schuller-Levis G (2002) Taurine chloramine inhibits lymphocyte proleration and decreases cytokine production in activated human leukocytes. Clin Immun102:179–184
40. Park E, Park SY, Dobkin C, Schuller-Levis G (2014) Development of a novel cysteine sulfinic decarboxylase knockout mouse: dietary taurine reduces neonatal mortality. J Amino Aci2014:346809
41. Parvez S, Tabassum H, Banerjee BD, Raisuddin S (2008) Taurine prevents tamoxifen-inducmitochondrial oxidative damage in mice. Basic Clin Pharmacol Toxicol 102:382–387
42. Patterson PH (2011) Maternal infection and immune involvement in autism. Trends Mol 17:389–394
43. Rossignol DA, Frye RE (2012) Mitochondrial dysfunction in autism spectrum disorders: a systeatic review and meta-analysis. Mol Psychiatry 17(3):290–314
44. Sandin S, Lichtenstein P, Kuja-Halkola R, Larsson H, Hultman CM, Reichenberg A (2014) familial risk of autism. JAMA 311(17):1770–1777
45. Schuller-Levis GB, Park E (2003) Taurine: new implications for an old amino acid. FEMMicrobiol Lett 226:195–202
46. Schuller-Levis G, Park E (2006) Is taurine a biomarker? Adv Clin Chem 41:1–21
47. Schuller-Levis G, Gordon RE, Park E, Pendino KJ, Laskin D (1995) Taurine protects rat broncoles from acute ozone-induced lung inflammation and hyperplasia. Exp Lung Res 21:877–8
48. Schuller-Levis G, Gordon R, Wang C, Park S, Park E (2009) Protection of bleomycin-inducfibrosis and inflammation by taurine. Int Immunopharmacol 9:971–977
49. Sealey LA, Hughes BW, Sriskanda AN, Guest JR, Gibson AD, Johnson-William L, Pace Bagasra O (2016) Environmental factors in the development of autism spectrum disorder Environ Int 88:288–298
50. Shetewy A, Shimada-Takaura K, Warner D, Jong CJ, Mehdi AB, Alexeyev M, Takahashi Schaffer SW (2016) Mitochondrial defects associated with β-alanine toxicity: relevance hyper-beta-alaninemia. Mol Cell Biochem 416(1–2):11–22
51. Shimada K, Jong CJ, Takhashi K, Schaffer SW (2014) Role of ROS production and turnover in antioxidant acidity of taurine. Adv Exp Med Biol 803:581–596
52. Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P, Zimmerman AW (2014) Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S 111(43):15550–15555
53. Sturman J (1993) Taurine in development. Physiol Rev 73(1):119–147
54. Sweeten TL, Bowyer SL, Posey DJ et al (2003) Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics 112(5):e420
55. Tu WJ, Chen H, He J (2012) Application of LC/MS/MS analysis of plasma amino acids profiles in children with autism. J Clin Biochem Nutr 51(3):248–249
56. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA (2005) Neuroglial activation and neuroinflammation in the brain of patient with autism. Ann Neurol 57:67–81
57. Wegiel J, Flory M, Kuchna I, Norwicki K, Ma SY, Wegiel J, Frackowiak J, Mazur-Kolecka B, Wierzba-Bobrowicz T, London E, Wisniewski T, Hof PR, Brown WT (2015) Neuronal nucleus and cytoplasm volume deficit in children with autism and volume increase in adolescents and adults. Acta Neuropathol Commun 3:2
58. White JF (2003) Intestinal pathophysiology in Autism. Exp Biol Med (Maywood) 228(6):639–649
59. Wink LK, Adams R, Wang Z, Klaunig JE, Plawecki MH, Posey DJ, McDougle CJ, Erickson CA (2016) A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism 7:26. doi:10.1186/s13229-016-0088-6. Ecollection 2016
60. Yap IK, Angley M, Veselkov KA, Holmes E, London JC, Nicholson JK (2010) Uninary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res 9(6):3996–4004